Recalls & Warnings
ConsumerLab.com is keeping you informed with current product recalls and warnings.
Posted August 8, 2022
Seller of CBD Warned for COVID-19 Claims
On August 4, 2022, the FDA sent a warning letter to FluxxLab LLC following a review of the company’s website and social media which found statements about the company’s Covid-19 Immune Support Tincture and CBDA+CBD Oil Tincture products to be drug claims because they are intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people.
For example, the company’s website promoted its CBD+CBDa Immune Support Special Formulation with statements such as, “Researchers discovered that cannabidiolic acid, also known as CBDA, binds to the spike protein of SARS-CoV-2, the virus that causes Covid-19. As the compounds bind to the spike protein, they prevent the virus from infecting cells and causing infection, opening up new avenues for the prevention and treatment of the disease.
FluxxLab LLC must respond to the FDA within 48 hours describing the specific steps it has taken to correct these violations.
For more information about related products, see ConsumerLab’s answer to the question: Do any supplements help with the coronavirus (COVID-19)? Do supplements like vitamin D, zinc, vitamin C, or herbals work?
Also see our CBD & Hemp Extract Supplements Review.
For more information, use the link below.
See related recalls and warnings:
CBD Products Were Promoted to Treat Cancer and Alzheimer’s Without Proof, Says FTC
Maker of Care by Design CBD Settles Charges of Unsupported Claims
CBD Seller Warned for Drug and COVID-19 Claims
FDA Warns Five Companies for Selling CBD Supplements, Gummies and Creams With Delta-8 THC
Seller of CBD Tinctures, Creams & Pet Produces Promoted for Pain, Cancer & More Warned by FDA